Evidence map›Paper›PMID 41416656›Full record

ArticleAllergy2026

Type I and II Interferons Drive Abacavir Hypersensitivity via Treg Suppression and T-Cell Enhancement in Immunocompetent HLA-Transgenic Mice.

SuJin Hwang, Telly Sepahpour, Stephanie Kortchak, Kirthiram Krishnaveni Sivakumar, Spyros Karaiskos, Ngoc Pham, Yura Jang, Montserrat Puig, Michael Norcross

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

SuJin HwangDivision of Product Quality Research 4, Office of Product Quality Research, Office of Product Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.ORCID https://orcid.org/0009-0002-2898-7348
Telly SepahpourDivision of Product Quality Research 4, Office of Product Quality Research, Office of Product Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Stephanie KortchakDivision of Product Quality Research 4, Office of Product Quality Research, Office of Product Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Kirthiram Krishnaveni SivakumarDivision of Product Quality Research 4, Office of Product Quality Research, Office of Product Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Spyros KaraiskosOffice of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Ngoc PhamDivision of Product Quality Research 4, Office of Product Quality Research, Office of Product Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Yura JangDivision of Product Quality Research 4, Office of Product Quality Research, Office of Product Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Montserrat PuigDivision of Product Quality Research 4, Office of Product Quality Research, Office of Product Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Michael NorcrossDivision of Product Quality Research 4, Office of Product Quality Research, Office of Product Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.

Funding

Oak Ridge Institute for Science and Education (ORISE)U.S. Food and Drug Administration
6 · The paper itself

Abstract

backgroundAbacavir (ABC)-induced hypersensitivity is associated with HLA-B*57:01, with tolerance maintained by regulatory T cells (Treg). This study hypothesized that the balance between Treg and CD8

methodsHLA-B*57:01 transgenic (Tg) mice and Tg mice lacking H2-K

resultsABC treatment of Tg/KO mice, which only express HLA-B*57:01 as an MHC-I allele, led to the expansion of drug-specific CD8

conclusionsIn vivo upregulation of HLA expression modulates the balance between drug-specific and regulatory T cells, thereby promoting optimal pDC expansion and enhancing IFN-α production, which counteracts Treg-mediated ABC tolerance. IFN-γ secretion by drug-specific CD8

Indexed as

DideoxynucleosidesDrug HypersensitivityHLA-B AntigensInterferon Type IT-Lymphocytes, RegulatoryAbacavirAnimalsCD8-Positive T-LymphocytesDendritic CellsDisease Models, AnimalHumansInterferon-gammaMiceMice, TransgenicAbacavirDideoxynucleosidesHLA-B AntigensInterferon-gammaInterferon Type Iabacavir hypersensitivity reaction (AHR)HLA‐B*57:01IFN‐αIFN‐γplasmacytoid DCregulatory T‐cells

Identifiers

PMID41416656
PMCPMC13342786

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.